logo
Leonard Lauder, philanthropist who globalized family cosmetic business, dies at age 92

Leonard Lauder, philanthropist who globalized family cosmetic business, dies at age 92

Associated Press4 hours ago

NEW YORK (AP) — Leonard Lauder, a renowned philanthropist who expanded the family cosmetics business into a worldwide empire, has died at the age of 92.
Estee Lauders Cos. announced the news in a release on Sunday and said he died on Saturday surrounded by family.
Lauder, the oldest son of Estee and Joseph H. Lauder, who founded the company in 1946, formally joined the New York business in 1958. Over more than six decades, Lauder played a key role in transforming the business from a handful of products sold under a single brand in U.S. stores to a multi-brand global giant. He had held the title of chairman emeritus at the time of his death.
Estee Lauder's products are sold in roughly 150 countries and territories under brand names including Clinique and Aveda, according to the company's latest annual report. The company generated sales of nearly $16 billion in the fiscal year ended June 30, 2024, the filing said.
Estee Lauder went public in 1995, but members of Lauder family still have about 84% of the voting power of common stock, according to the latest annual filing.
Lauder served as president of The Estée Lauder Cos. from 1972 to 1995 and as CEO from 1982 through 1999. He was named chairman in 1995 and served in that role through June 2009.
Under his stewardship, Lauder created the company's first research and development laboratory, brought in professional management at every level, and was the impetus behind The Estée Lauder Cos.' international expansion, helping to spearhead the company's sales and profits exponentially, according to the company.
Lauder led the launch of many brands including Aramis, Clinique, and Lab Series, among others. Until his death, he remained deeply involved in the company's acquisition strategy, including the acquisitions of such brands as Aveda, Bobbi Brown, Jo Malone London and MAC, the company said.
During his years as chairman emeritus, Lauder was closely involved in the business and day-to-day operations and was a constant fixture at its global headquarters in New York and at its stores around the world until the time of his death, the company said.
'Throughout his life, my father worked tirelessly to build and transform the beauty industry, pioneering many of the innovations, trends, and best practices that are foundational to the industry today,' said William P. Lauder, son and chair of the board at The Estée Lauder Companies in a statement. 'He was the most charitable man I have ever known, believing that art and education belonged to everyone, and championing the fight against diseases such as Alzheimer's and breast cancer. '
Lauder was a longtime patron of the Metropolitan Museum of Art and, in 2013, pledged his 78-piece collection of Cubist art to the museum in the largest single philanthropic gift in the museum's history. He later added five major works to that pledged gift, the company said.
In concert with his Cubist collection donation, he helped establish the Leonard A. Lauder Research Center for Modern Art at the Met to support a program of fellowships, focused exhibitions, and public lectures. He also was the Whitney Museum of American Art's chairman emeritus and a trustee from 1977 to 2011.
Lauder was married to Evelyn H. Lauder, who had been the senior corporate vice president at the cosmetic company and the founder of the Breast Cancer Research Foundation, from 1959 until she passed away in 2011.
On Jan. 1, 2015, Lauder married Judy Glickman Lauder, a philanthropist and internationally recognized photographer.
Lauder was born in 1933 in New York City. He was a graduate of the Bronx High School of Science, the University of Pennsylvania's Wharton School, and the Officer Candidate School of the United States Navy.
Lauder studied at Columbia University's graduate school of business. He served as a lieutenant in the U.S. Navy and as a Navy reservist, for which the U.S. Navy Supply Corps Foundation later recognized him with its Distinguished Alumni Award.
In addition to his wife and son William, Lauder is survived by his other son Gary M. Lauder and wife, Laura Lauder; five grandchildren, two great-grandchildren, many stepchildren and step grandchildren, as well as his brother, Ronald S. Lauder, and wife, Jo Carole Lauder, and their daughters, Aerin Lauder and Jane Lauder.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US and UK say they've cemented a trade agreement that Trump calls fair for both nations
US and UK say they've cemented a trade agreement that Trump calls fair for both nations

Washington Post

time12 minutes ago

  • Washington Post

US and UK say they've cemented a trade agreement that Trump calls fair for both nations

BANFF, Alberta — President Donald Trump and Prime Minister Keir Starmer said Monday that they are signing a trade deal that will slash tariffs on goods from both countries. The deal does not include tariffs on steel, an especially important piece of bilateral trade. Instead, talks are still going on about whether steel tariffs will be cut to zero as planned in the provisional agreement.

Biotech pauses trial after second patient death linked to gene therapy
Biotech pauses trial after second patient death linked to gene therapy

Washington Post

time12 minutes ago

  • Washington Post

Biotech pauses trial after second patient death linked to gene therapy

Biotech firm Sarepta Therapeutics said that a second patient died after receiving its gene therapy to treat Duchenne muscular dystrophy, the latest drug to draw scrutiny after winning fast regulatory approval. The Cambridge, Massachusetts-based firm's stock lost more than 40 percent of its value Monday, a day after disclosing the death and announcing that it would temporarily stop shipping the treatments for certain patients, and pause a clinical trial, while it evaluates its protocols.

Eli Lilly is making it cheaper and easier to buy high-doses of blockbuster weight loss drug Zepbound
Eli Lilly is making it cheaper and easier to buy high-doses of blockbuster weight loss drug Zepbound

Fast Company

time14 minutes ago

  • Fast Company

Eli Lilly is making it cheaper and easier to buy high-doses of blockbuster weight loss drug Zepbound

Eli Lilly announced on Monday it will soon make the two highest-doses of its popular weight-loss drug Zepbound available for self-paying customers on its website. Starting in August, 12.5 mg and 15 mg single-doses will be added to the company's website, effectively making all Zepbound doses available for $499 a month, or less. Unlike the pen form sold at pharamcies like Walgreens and CVS, the drug will be available in vial form through its LillyDirect self-pay pharmacy, which will require patients to draw their own shots into a syringe rather than have them prefilled. The drug will be to any eligible adult with obesity and a valid prescription regardless of insurance coverage. Health care providers and doctors can start prescribing the higher doses on July 7, according to Lilly. Zepbound is an injectable prescription medicine that belongs to a class of drugs known as GLP-1 receptor agonists originally developed for type 2 diabetes, that may help adults for treating obesity and weight-related medical issues. 'Obesity is a serious, chronic disease, and access to obesity medications should be treated with the same urgency as other chronic conditions,' Rhonda Pacheco, group vice president of U.S. Cardiometabolic Health at Lilly said in the press release. 'Lilly was the first company to offer a self-pay solution for an FDA-approved obesity medication, and we continue to work to expand coverage for Zepbound. In the meantime, the availability of the two highest-dose Zepbound vials gives providers and patients another important treatment option.' While the weight-loss drugs are popular with consumers, not so much with insurance companies, who don't always widely cover the drugs, leading Lily, and rival Novo Nordisk, the maker of Wegovy, to start offering their own self-pay options. The company first rolled out its self-pay, single-dose vials last summer in an effort to meet high consumer demand. Shares in the (NYSE: LLY) were trading down less than 2% at the market's close on Monday. Eli Lily: By the numbers In Eli Lily's latest round of earnings for the first quarter of 2025, ending March 31, 2025, the company showed a mixed performance, and reported net income of $2.76 billion and earnings per share (EPS) of $3.34, with revenue guidance between $58 billion and $61 billion. The drug maker has a market capitalization of $724.99 billion, as of this writing.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store